Skip to main content

stock

CGEM · Cullinan Therapeutics, Inc.

What Cullinan Therapeutics, Inc. reports to the SEC, read from its filings.

Open in the app

Price

The live CGEM price and today's change.

Sign in to see this

Chart

Thirty days of daily bars, with signal levels drawn on them.

Sign in to see this

Signals

The latest signal group Nakagai's scanner recorded on CGEM.

Sign in to see this

Options positioning

Gamma exposure levels from the options market.

Sign in to see this

Technicals

Trend, momentum and volatility gauges per timeframe.

Sign in to see this

What it is

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Filer (SEC EDGAR)
EDGAR filing index
Shares outstanding
64,354,694 as of 2026-07-31 (XBRL frame CY2026Q2I)

Key stats

Valuation

P/E
Locked
P/S
Locked
P/B
Locked
Enterprise value
Locked
EV/EBIT
Locked
FCF yield
Locked

Margins

Gross
—
Operating
—
Net
—

Returns

ROE
-63.6%
ROA
-56.3%

Health

Current ratio
8.4x
Debt/equity
—

Deep value

NCAV
$299.94M
NCAV per share
$4.66
Price/NCAV
Locked
NNWC
$36.61M
NNWC per share
$0.57
Price/NNWC
Locked

Valuation and the price multiples are built on the live price. Trailing twelve months to 2026-06-30; balance sheet at 2026-06-30.

Sign in to see this

Debt is long-term debt and its current portion. Commercial paper and short-term borrowings are not counted.

Results

Period endRevenueGross profit (not reported by this company)Operating incomeNet incomeFiling
2026-06-30——Gross profit: unreported by this company.-$57.25M-$53.70M
10-Q filed 2026-08-06
2026-03-31——Gross profit: unreported by this company.-$53.70M-$49.66M
10-Q filed 2026-08-06
Assembled from more than one filing; the filing above is only the newest of them.
2025-12-31——Gross profit: unreported by this company.-$55.26M-$50.71M
DEF 14A filed 2026-04-28
Derived: the full year minus the first three quarters, not a figure this filer reported as a quarter.
Assembled from more than one filing; the filing above is only the newest of them.
2025-09-30——Gross profit: unreported by this company.-$55.59M-$50.61M
10-Q filed 2025-11-06
2025-06-30——Gross profit: unreported by this company.-$75.80M-$70.06M
10-Q filed 2026-08-06
Assembled from more than one filing; the filing above is only the newest of them.
2025-03-31——Gross profit: unreported by this company.-$55.00M-$48.50M
10-Q filed 2026-05-07
Assembled from more than one filing; the filing above is only the newest of them.
2024-12-31——Gross profit: unreported by this company.-$55.05M-$47.84M
DEF 14A filed 2026-04-28
Derived: the full year minus the first three quarters, not a figure this filer reported as a quarter.
Assembled from more than one filing; the filing above is only the newest of them.
2024-09-30——Gross profit: unreported by this company.-$48.85M-$40.56M
10-Q filed 2025-11-06
Assets
$363.79M
Equity
$321.75M

Balance as of 2026-06-30.

Ten years

Fiscal year endRevenueOperating incomeNet incomeFree cash flow
2025-12-31—-$241.65M-$219.88M-$175.80M
2024-12-31—-$196.92M-$167.57M-$145.30M
2023-12-31—-$191.09M-$155.10M-$134.48M
2022-12-31$0$144.65M$111.21M-$127.80M
2021-12-31$18.94M-$67.95M-$65.57M-$43.43M
2020-12-31$0-$60.34M-$51.80M-$29.78M

Company filings

Insiders, politicians and funds

Insider trades, last 90 days

  • Michaelson Jennifer

    Chief Scientific Officer

    Sale$172,560

    Sep 10, 9:22 AM ET

  • Michaelson Jennifer

    Chief Scientific Officer

    Sale$607,800

    Aug 14, 5:00 PM ET

All insider trades for CGEM

Politician trades, last 90 days

Funds

  • Point72

    Period Tue 30 Jun 2026

    0.0%Trimmed

All funds

News

Stories that named CGEM, and the market events around them.

Sign in to see this

Board

The CGEM board could not be loaded.

Retry the CGEM board

nakagai

Signals on CGEM come from a rule, not a model.

Nakagai’s scanner records a signal the moment a strategy’s rule matches on the bars. Members read those signals on their own desk, where an agent journals the tape and briefs them in plain English.

Members post on the CGEM board

This page is not financial advice. Trade at your own judgment and risk. Read the terms that govern posting here.

Cullinan Therapeutics, Inc. (CGEM): SEC filings, financials and insider trades · Nakagai